Recently, phase III trials showed that combination therapy of ICIs and platinum‐based chemotherapy as first‐line treatment in NSCLC patients has a higher objective response rate (ORR) and offers longer progression‐free survival (PFS) and OS than chemotherapy alone, regardless of the PD‐L1 TPS.7, 8, 9. The gene discussed is CD274; the disease is non-small cell lung carcinoma.